Steven, those market projections are massive but the roll out...

Steven, those market projections are massive but the roll out will be very slow. Not sure if the US insurers cover the test at this stage, BDX might need a National Comprehensive Cancer Network® (NCCN) recommendation that forces private and public health insurers to refund the test costs. Despite the tests will help to reduce costs in the billions insurers are very slow in adopting and adjusting and hospitals are reluctant to recommend tests if those aren't covered. Should the strategy include a self test beside the health system, like a COVID - Test, then of course that obstacle would be removed but then they need a US wide marketing campaign.

I would like to dampen the $$$ expectations, it will take time. At IPD they got the best screening tool in the world for bioimpedance spectroscopy (BIS) as a recommended option to identify early signs of lymphoedema, all approvals and the NCCN recommendation and yet, the roll out is " Continental Drift Slow " due to the Slow Motion pace of hospitals and insurers.

Australia could be different, but even then costs will still be higher than revenue for a while.

GLTA